PT3533447T - Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração - Google Patents

Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração

Info

Publication number
PT3533447T
PT3533447T PT191511526T PT19151152T PT3533447T PT 3533447 T PT3533447 T PT 3533447T PT 191511526 T PT191511526 T PT 191511526T PT 19151152 T PT19151152 T PT 19151152T PT 3533447 T PT3533447 T PT 3533447T
Authority
PT
Portugal
Prior art keywords
bendamustine
administration
liquid compositions
treating
patients requiring
Prior art date
Application number
PT191511526T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3533447(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of PT3533447T publication Critical patent/PT3533447T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PT191511526T 2012-03-20 2013-03-15 Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração PT3533447T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613173P 2012-03-20 2012-03-20
US201261669889P 2012-07-10 2012-07-10
US201261678715P 2012-08-02 2012-08-02

Publications (1)

Publication Number Publication Date
PT3533447T true PT3533447T (pt) 2023-05-17

Family

ID=49212373

Family Applications (2)

Application Number Title Priority Date Filing Date
PT191511526T PT3533447T (pt) 2012-03-20 2013-03-15 Composições líquidas de bendamustina para utilização num método de tratamento de condições com resposta a bendamustina em pacientes que requerem volumes reduzidos para administração
PT13765020T PT2827863T (pt) 2012-03-20 2013-03-15 Composição líquida para utilização num método de tratamen-to de condições responsivas a bendamustina em pacientes que requerem volumes reduzidos para administração

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT13765020T PT2827863T (pt) 2012-03-20 2013-03-15 Composição líquida para utilização num método de tratamen-to de condições responsivas a bendamustina em pacientes que requerem volumes reduzidos para administração

Country Status (17)

Country Link
US (3) US9000021B2 (enExample)
EP (3) EP3533447B1 (enExample)
JP (6) JP6224064B2 (enExample)
CN (2) CN104271135B (enExample)
CA (1) CA2867343C (enExample)
DK (2) DK2827863T3 (enExample)
ES (2) ES2943668T3 (enExample)
FI (1) FI3533447T3 (enExample)
HK (1) HK1243346A1 (enExample)
HR (2) HRP20190693T1 (enExample)
HU (2) HUE044233T2 (enExample)
LT (1) LT2827863T (enExample)
PL (2) PL2827863T3 (enExample)
PT (2) PT3533447T (enExample)
RS (2) RS58744B1 (enExample)
SI (2) SI2827863T1 (enExample)
WO (1) WO2013142359A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054836T2 (hu) 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
JP6224064B2 (ja) 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
HRP20240056T1 (hr) * 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
CA3108321A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
JPWO2021014957A1 (enExample) * 2019-07-22 2021-01-28
WO2021161876A1 (ja) * 2020-02-10 2021-08-19 富士フイルム株式会社 ベンダムスチン液剤
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
NZ279443A (en) 1994-01-24 1998-04-27 Procter & Gamble Solubilizing difficultly soluble pharmaceutical agents using a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol
EP1004305B1 (en) 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
ES2300622T3 (es) 2002-07-30 2008-06-16 Wyeth Formulaciones parenterales que contienen un hidroxiester de rapamicina.
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
CA2585659A1 (en) 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2007026771A1 (ja) * 2005-08-31 2007-03-08 Ono Pharmaceutical Co., Ltd. 点滴用注射剤
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) * 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
EP2424506A1 (en) 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine
CN101584668A (zh) * 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
HUE054836T2 (hu) 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
US8604032B2 (en) * 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
AU2012347972B2 (en) 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
JP2015506989A (ja) 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
JP6224064B2 (ja) 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
HRP20240056T1 (hr) 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina

Also Published As

Publication number Publication date
DK3533447T3 (da) 2023-04-24
JP2022028813A (ja) 2022-02-16
PL3533447T3 (pl) 2023-07-17
JP2015510940A (ja) 2015-04-13
RS58744B1 (sr) 2019-06-28
PL2827863T3 (pl) 2019-07-31
CN107157988A (zh) 2017-09-15
WO2013142359A1 (en) 2013-09-26
SI2827863T1 (sl) 2019-06-28
US9579384B2 (en) 2017-02-28
HRP20230276T1 (hr) 2023-04-28
HRP20190693T1 (hr) 2019-10-04
US20130253026A1 (en) 2013-09-26
US20150080444A1 (en) 2015-03-19
JP2024037915A (ja) 2024-03-19
CA2867343A1 (en) 2013-09-26
HUE044233T2 (hu) 2019-10-28
JP2018197248A (ja) 2018-12-13
EP2827863B1 (en) 2019-01-16
CN104271135B (zh) 2017-05-17
FI3533447T3 (fi) 2023-05-04
CA2867343C (en) 2020-08-11
LT2827863T (lt) 2019-06-10
EP3533447B1 (en) 2023-03-15
RS64137B1 (sr) 2023-05-31
SI3533447T1 (sl) 2023-06-30
US9000021B2 (en) 2015-04-07
HUE062230T2 (hu) 2023-10-28
JP6224064B2 (ja) 2017-11-01
US20150343061A1 (en) 2015-12-03
HK1243346A1 (zh) 2018-07-13
PT2827863T (pt) 2019-05-13
EP3533447A1 (en) 2019-09-04
EP2827863A4 (en) 2015-11-18
ES2718902T3 (es) 2019-07-05
CN104271135A (zh) 2015-01-07
ES2943668T3 (es) 2023-06-15
JP2018048153A (ja) 2018-03-29
JP2020143143A (ja) 2020-09-10
JP6738376B2 (ja) 2020-08-12
JP6381761B2 (ja) 2018-08-29
EP4218756A1 (en) 2023-08-02
DK2827863T3 (en) 2019-04-23
EP2827863A1 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
PL3533447T3 (pl) Ciekłe kompozycje bendamustyny do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
IL249991A0 (en) Methods of treating sick children by dexmedetomidine
IL239557A0 (en) Microarray for providing therapeutic material and methods for use
EP2811897A4 (en) MEDICAL TERMINAL AND APPLICATION METHOD
IL237318B (en) Chemical preparations and methods for increasing the delivery of therapeutic agents through the skin
HUE044611T2 (hu) Gyógyászati készítmény rák kezelésére
PL2824114T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
IL227624A0 (en) Empty nano-particle compounds and their use for the treatment of skin conditions
PL2773648T3 (pl) Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile
PL2644215T3 (pl) Aparat do pozaustrojowej obróbki krwi
GB2523055B8 (en) Ophthalmic devices for delivery of beneficial agents
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
ZA201408993B (en) Pharmaceutical formulation for bedwetting and method of use thereof
EP2726079A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
SG11201504068UA (en) Orally administered liquid formulation
HUP1200552A2 (en) Pharmaceutical compositions for the treatment of high blood pressure
EP2838551A4 (en) USE OF THYMOSIN ALPHA FOR THE TREATMENT OF PURULENT RHINO-SINUSITIS
IL210808A0 (en) System and method for treatment of liquid
EP2854878A4 (en) MEDICAL DEVICE FOR TREATING WOUNDS